Corbus Pharmaceuticals Holdings, Inc.
CRBPDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How CRBP's past catalysts played out
Lenabasum 5 mg
Dermatomyositis
Lenabasum 20 mg
Cystic Fibrosis
JBT-101 (lenabasum)
Cystic Fibrosis
CRB-601 monoclonal antibody
Solid Tumor
CRB-701
Solid Tumor, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lenabasum 5 mg | Phase 3 | Dermatomyositis | - | - |
Lenabasum 20 mg | Phase 3 | Cystic Fibrosis | - | - |
JBT-101 (lenabasum) | Phase 2 | Cystic Fibrosis | - | - |
CRB-601 monoclonal antibody | Phase 2 | Solid Tumor | - | - |
CRB-701 | Phase 2 | Solid Tumor, Adult | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Corbus Pharmaceuticals Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) pipeline across Phase 3, Phase 2. Its lead program is Lenabasum 5 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Corbus Pharmaceuticals Holdings, Inc.'s next FDA catalyst?→
Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRBP biotech catalysts?→
Add CRBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Corbus Pharmaceuticals Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.